JNJan Nowak

Jan Nowak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan Nowak has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ONCOPLASTIC BREST SURGERY IN BREST CANCER TREATMENT: POSITIVE EFFECTS ON PATIENT WELL-BEING AFTER COMBINED ONCOLOGICAL AND PLASTIC SURGICAL PROCEDURES

    by Anna Cupiał, Stella Mieruszyńska, Jagoda Mikołajczyk, Artur Hawajski, Weronika Mielnicka, Jan Nowak., Julia Sławińska, Olga Szeidl, Maja Kołodziejska, Marcin Lewandowski

    Oncoplastic breast surgery is a rapidly evolving field that combines oncologic surgery with plastic and reconstructive surgery. From the perspective of oncologic surgery, the primary objective is effective cancer treatment, which means achieving clear surgical margins (i.e. oncological radicality). Equally important, however, are the preservation of breast function and the achievement of a satisfactory aesthetic outcome through the integration of oncologic and plastic surgical techniques. The aesthetic result of surgical breast cancer treatment can significantly enhance the recovery process and positively influence the overall effectiveness of treatment. The aim of this publication is to present various surgical techniques used in therapeutic breast tumor excision combined with immediate breast reconstruction, using either the patient's own tissues or breast implants, and to discuss their impact on patient satisfaction. Selecting the most appropriate treatment method is crucial and depends on numerous factors. An individualized approach to each patient , as well as the careful selection of the optimal surgical technique, are essential for achieving satisfactory outcomes. The integration of oncologic and plastic surgical techniques in breast surgery has a positive effect on patients' physical and psychological well-being following treatment. These procedures help patients cope more effectively with the challenges of cancer therapy, adapt to visible changes in their bodies, and return to their normal lives. In addition, this publication briefly discusses the prevention and diagnosis of breast diseases in women.

  • Open Access

    Zolpidem in the treatment of insomnia: Mechanism of action, risk of dependence, and withdrawal syndrome

    by Julia Sławińska, Weronika Mielnicka, Jagoda Mikołajczyk, Artur Hawajski, Jan Nowak, Stella Mieruszyńska, Olga Szeidl, Maja Kołodziejska, Marcin Lewandowski, Anna Cupiał

    Pharmacotherapy in Psychiatry and Neurology

  • Open Access

    MATERNAL AND FETAL OUTCOMES ASSOCIATED WITH RUNNING DURING PREGNANCY: A SYSTEMATIC REVIEW

    by Jan Nowak, Olga Szeidl, Jagoda Mikołajczyk, Artur Hawajski, Weronika Mielnicka, Stella Mieruszyńska, Julia Sławińska, Maja Kołodziejska, Marcin Lewandowski, Anna Cupiał

    Introduction: Running is one of the most popular forms of physical activity among women of reproductive age; however, pregnancy and the postpartum period involve substantial physiological, biomechanical, and psychosocial changes that may affect training continuation and safe return to sport. Body mass gain, a shift in the center of gravity, increased joint laxity, and cardiovascular and respiratory adaptations alter running biomechanics and may influence musculoskeletal load and pelvic floor function. Evidence suggests that physical activity during pregnancy is associated with improved well-being, weight control, and metabolic outcomes, while supervised exercise may enhance mental health and selected cardiometabolic markers. At the same time, appropriate monitoring of exercise intensity and individualized load adjustment remain essential, particularly in competitive athletes. Return to running postpartum should follow a staged, criteria-based approach that considers biopsychosocial factors. Overall, running during pregnancy represents a complex issue requiring interdisciplinary, evidence-based guidance. This systematic review critically synthesizes current literature, highlighting benefits, limitations, and gaps to inform future research and clinical practice. Methods: This review synthesizes recent literature (2015–2026) on running and pregnancy. A comprehensive search of PubMed, Scopus, and Google Scholar was conducted using keywords including "running", "pregnancy", "physical activity", "pregnant", "maternity" and "mother well-being". All relevant studies were considered to provide an inclusive overview of current evidence. Aim of The Study: The aim of this perspective review is to synthesize and critically evaluate current research on the effects of running on pregnancy as documented in the recent literature. Conclusion: The literature review indicates that running during pregnancy—when no medical contraindications are present and training loads are appropriately modified—may represent a safe and potentially beneficial form of physical activity. Individual context remains crucial, including pre-pregnancy fitness level, health status, pregnancy course, and the quality of medical and physiotherapeutic support. Current evidence suggests that moderate running may support weight control, metabolic profile, and cardiorespiratory fitness without increasing the risk of preterm birth in healthy women. However, the high prevalence of musculoskeletal complaints and the potential risk of pelvic floor dysfunction highlight the need for functional assessment and targeted stabilization training. Postpartum return to running should follow a staged, criteria-based approach rather than a purely time-based model. Although existing evidence is heterogeneous and largely observational, individualized, evidence-based recommendations and interdisciplinary care appear essential for safe and effective practice.

  • Open Access

    KETAMINE IN THE TREATMENT OF DEPRESSION - A REVIEW ARTICLE

    by Olga Szeidl, Jagoda Mikołajczyk, Artur Hawajski, Weronika Mielnicka, Jan Nowak, Stella Mieruszyńska, Julia Sławińska, Maja Kołodziejska, Marcin Lewandowski, Anna Cupiał

    Background: Depression is a multifactorial disorder involving neurotransmitter dysregulation, HPA axis hyperactivity, neuroinflammation, and impaired neuroplasticity. While combination psychotherapy and pharmacotherapy remains first-line, ~30% of patients develop TRD. In the last few years ketamine has emerged as a rapid-acting therapeutic option for treatment-resistant cases. Aim: To review the etiology, treatment options, and emerging interventions for major depressive disorder (MDD), with a particular focus on treatment-resistant depression (TRD) and the therapeutic potential of ketamine and ketamine-assisted psychotherapy (KAP). Methods: A comprehensive literature review was conducted, analyzing 29 studies from the PubMed database (English-language, up to October 2025) that assess the etiology, treatment options of depression with emphasis on the therapeutic role of ketamine, especially in treatment-resistant depression (TRD). Results: Subanesthetic intravenous or intranasal ketamine produces rapid antidepressant effects within hours, reduces suicidal ideation, and enhances synaptic connectivity through AMPA receptor, BDNF, and mTOR signaling. KAP leverages this neuroplastic window to consolidate cognitive and emotional restructuring. Intranasal esketamine has received FDA and EMA approval as adjunctive therapy for TRD. Ketamine is generally well-tolerated, though patient selection, monitoring, and adherence to safety protocols are essential. Conclusions: Ketamine and KAP represent transformative interventions for TRD, offering rapid symptom relief and potential enhancement of psychotherapeutic outcomes. Further large-scale, randomized studies are required to optimize treatment protocols, understand long-term efficacy, and determine the additive benefits of psychotherapy.

  • Open Access

    Neurological and neuroinflammatory consequences of exposure to e-cigarette aerosols – a systematic review of experimental and clinical data

    by Weronika Mielnicka, Julia Sławińska, Jagoda Mikołajczyk, Artur Hawajski, Jan Nowak, Stella Mieruszyńska, Olga Szeidl, Maja Kołodziejska, Marcin Lewandowski, Anna Cupiał

    Electronic cigarette aerosols contain numerous chemicals that can affect the central nervous system through mechanisms involving oxidative stress, inflammatory processes, and blood–brain barrier dysfunction. When the liquid is heated, aldehydes, heavy metals, free radicals, and pyrolysis products of propylene glycol and glycerine are formed. These compounds lead to damage to endothelial structures, degradation of tight junction proteins, and increased blood–brain barrier permeability, which promotes the penetration of pro-inflammatory cytokines and the activation of microglia and astroglia. Preclinical studies have shown increased production of inflammatory mediators, disturbances in mitochondrial homeostasis, and changes in the functioning of transporters responsible for neuronal metabolism. Nicotine present in aerosols modulates the activity of nicotinic acetylcholine receptors, affecting dopaminergic, glutamatergic, and GABAergic transmission. These changes lead to neuroadaptation within the mesolimbic reward system and promote the reinforcement of addictive behaviours. Some aromatic compounds, including menthol and farnesol, may further exacerbate oxidative stress and enhance the effects of nicotine. Evidence from animal studies indicates that chronic exposure to electronic cigarette aerosols may lead to cognitive impairment, behavioural changes, and increased susceptibility to neurodegenerative processes, especially during developmental periods. Despite the growing number of mechanistic studies, clinical data remain limited. This paper summarises the current state of knowledge on the neurotoxic potential of electronic cigarette aerosols, with particular emphasis on molecular and cellular mechanisms, and highlights the need for further research into their long-term effects on the nervous system.

  • Open Access

    THE INFLUENCE OF CANNABIS ON THE DEVELOPMENT OF SCHIZOPHRENIA - A REVIEW

    by Artur Hawajski, Weronika Mielnicka, Jan Nowak, Stella Mieruszyńska, Julia Sławińska, Olga Szeidl, Maja Kołodziejska, Marcin Lewandowski, Anna Cupiał, Jagoda Mikołajczyk

    Background: Schizophrenia is a complex mental disorder influenced by both genetic and environmental factors. Cannabis use, particularly products with high tetrahydrocannabinol (THC) content, has been identified as a potential environmental risk factor for psychosis. Aim: This review aims to summarize current knowledge on the epidemiology, etiopathogenesis, and risk factors of schizophrenia, with a particular focus on the impact of marijuana use on the development of psychotic symptoms. Methods: A narrative synthesis of epidemiological, genetic, neurobiological, and clinical studies was conducted, including analyses of cannabis use, THC potency, and age of first exposure. Results: Evidence indicates strong familial aggregation of schizophrenia and sex-related differences in the age of onset. Genetic studies highlight polygenic susceptibility, dopaminergic and glutamatergic dysregulation, and the impact of prenatal and early-life exposures. High-THC cannabis use, especially during adolescence, is associated with increased risk of psychotic symptoms, earlier onset, and more severe disease progression. Rising THC concentrations and increasing cannabis consumption pose significant public health challenges. Conclusions: Understanding the dose-dependent effects of cannabis on schizophrenia is critical for prevention strategies and public health policy, particularly in the context of increasing legalization and product potency.

  • Open Access

    DEVELOPMENTAL CARDIAC ANOMALIES IN CHILDREN WITH EDWARDS SYNDROME: A COMPREHENSIVE REVIEW

    by Dominik Szklarkowski, Klaudia Romejko, Wiktor Kubik, Michał Górski, Jan Nowak, Barbara Kujawa, Bartosz Zwoliński, Kacper Sukiennicki, Wirginia Bertman, Natalia Kołdej, et al.

    Introduction and objective: Edwards Syndrome, also known as Trisomy 18, is the second most common autosomal trisomy following Down Syndrome. This chromosomal disorder is characterized by the presence of a third copy of chromosome 18, in contrast to the usual two. The condition is associated with a wide spectrum of severe congenital anomalies, significant developmental delays, and a high rate of fetal loss and infant mortality. Therefore, a comprehensive synthesis of these associated developmental anomalies is crucial for accurate prenatal counseling, clinical guidance, and postnatal management. The primary objective of this comprehensive review is to systematically identify, collate, and synthesize the existing literature regarding the range and prevalence of congenital heart defects in children diagnosed with Edwards Syndrome. Recognizing that cardiac anomalies are a cardinal feature and a leading cause of mortality in this condition, this review aims to provide a detailed, evidence-based overview of these specific manifestations. Ultimately, this focused analysis seeks to enhance clinical understanding of the cardiovascular complications in Edwards Syndrome and inform targeted management strategies. Brief description of the state of knowledge: Edwards Syndrome (Trisomy 18) is characterized by a high burden of congenital anomalies, with cardiac defects affecting the vast majority of patients and serving as a primary determinant of survival. Historically regarded as a uniformly lethal condition requiring only palliative care, the clinical perspective is evolving. Recent data indicate that cardiac interventions may offer survival benefits, challenging traditional non-interventional paradigms and necessitating an updated understanding of the cardiovascular phenotype. Methods: A systematic literature review was performed by searching major biomedical databases (PubMed, Google Scholar, Elicit) using a combination of keywords and MeSH terms, including "Edwards Syndrome" and "congenital abnormalities." Inclusion criteria prioritized peer-reviewed articles such as case series, observational studies, and systematic reviews. Data extraction focused on the types, frequency, and systemic impact of anomalies, as well as postnatal developmental outcomes. The collected data were then synthesized to create a comprehensive syndrome profile. Conclusions: The clinical paradigm for Edwards Syndrome is shifting from a uniform designation of lethality toward a personalized, multidisciplinary model. Accurate prenatal diagnosis via fetal echocardiography is essential for early risk stratification. Contemporary management requires a balanced approach integrating palliative care with the option of active cardiac intervention. Consequently, parental counseling must emphasize shared decision-making, providing families with evidence-based data on potential surgical outcomes to optimize the quality of life for the affected child.

  • Open Access

    ROLE OF HIF-1 SIGNALING PATHWAY IN CELLULAR ADAPTATION TO HYPOXIA

    by Kamil Borysewicz, Illia Koval, Wiktor Kubik, Bartłomiej Czarnecki, Jan Nowak, Barbara Kujawa, Bartosz Zwoliński, Kacper Sukiennicki, Wirginia Bertman, Natalia Kołdej, et al.

    Hypoxia accompanying chronic inflammatory diseases leads to dysregulation of cells’ homeostasis, causes energy deficits and intensifies inflammatory processes. Hypoxia-inducible factors (HIFs) are the central regulators of the response to hypoxia, enabling metabolic and functional adaptation of immune cells by altering gene expression. HIF-1α and HIF-2α modulate the lifespan, differentiation, priming and activation of neutrophils, macrophages, lymphocytes, and dendritic cells- playing a key role in influencing the balance between proinflammatory and reparative responses. Interactions between HIF and NF-κB pathways regulate hypoxic and inflammatory signaling, and as a result determine course, severity and treatment efficacy of many chronic diseases. Those two pathways are capable of influencing each other in a manner of negative feedback-loop. Understanding the mechanisms of this regulation opens up new therapeutic perspectives in the treatment of pulmonary diseases associated with hypoxia and inflammation, and a hypothetical possibility to slow down the ratio at which chronic inflammatory response contributes to deterioration of patients’ quality of life.

  • Open Access

    LIVING AGAINST THE CLOCK: A NARRATIVE REVIEW OF SOCIAL JETLAG, HEALTH CONSEQUENCES, AND MODIFIABLE RISK FACTORS

    by Katarzyna Szewczyk, Wirginia Bertman, Klaudia Romejko, Kamil Borysewicz, Zuzanna Kępczyńska, Wiktor Kubik, Bartłomiej Czarnecki, Barbara Kujawa, Jan Nowak, Bartosz Zwoliński, et al.

    Objective: This review examines the prevalence, causes, and health impacts of social jetlag (SJL), a chronic circadian misalignment arising from mismatches between biological sleep-wake timing and socially imposed schedules. It synthesizes contemporary knowledge on SJL’s epidemiology, measurement, biological mechanisms, and public health relevance. Background: SJL has become increasingly common among adolescents and shift workers, driven by factors such as early school start times, rotating work shifts, and increased nighttime digital screen use. These influences disrupt regular sleep patterns, resulting in persistent conflicts with endogenous circadian rhythms. Methods: A narrative review was conducted including peer-reviewed studies from 2015 to 2025, with one foundational exception (Wittmann et al., 2006). Databases searched were PubMed, Scopus, Web of Science, and Google Scholar. Studies were included based on relevance to SJL, circadian misalignment, and health outcomes in humans. Results: Literature indicates SJL is linked to elevated cardiometabolic risks, including type 2 diabetes, obesity, and systemic inflammation. In adolescents and young adults, SJL is also associated with poor sleep quality, increased daytime sleepiness, and higher depressive symptom rates. Objective measures, like actigraphy and biomarkers, support these findings. Social and institutional timing structures are modifiable contributors to SJL. Discussion: SJL is a measurable and harmful circadian disruption with short-term effects such as fatigue and cognitive impairments and long-term impacts including metabolic and mental health disorders. Despite evidence growth, longitudinal and intervention research remains limited, hindering population-level mitigation strategies. Conclusion: SJL is a common, modifiable circadian health issue linked to broad physiological and psychological risks. Interventions like delaying school starts and chronotype-personalized shift schedules could alleviate SJL’s burden and improve long-term public health.


  • Open Access

    REVOLUTIONIZING THERAPEUTIC APPROACHES IN CHRONIC VENOUS INSUFFICIENCY: A LITERATURE REVIEW

    by Bartłomiej Czarnecki, Jan Nowak, Illia Koval, Bartosz Zwoliński, Kacper Sukiennicki, Wirginia Bertman, Natalia Kołdej, Zuzanna Kępczyńska, Wiktor Kubik, Katarzyna Szewczyk, et al.

    Introduction: Chronic venous insufficiency (CVI) is a prevalent, progressive vascular disorder that burdens patient health and quality of life. Current treatments: compression therapy, pharmacological agents, and surgery vary in efficacy and are often linked to poor symptom control, recurrence, or side effects. Thus, there is a need for novel therapies that improve outcomes. Recent advances in pharmacotherapy and minimally invasive methods offer promising options for enhancing venous function and symptom relief. This study critically assesses the efficacy, safety, and clinical relevance of emerging pharmacological and interventional treatments for CVI. Material and methods: A comprehensive literature search was conducted in PubMed and Google Scholar using keywords: "chronic venous insufficiency", "venous disease", "novel treatment", "minimally invasive therapy", "pharmacological therapy". Selected studies were analyzed for therapeutic efficacy, safety, and clinical outcomes of proposed treatments. Aim of the study To evaluate the effectiveness, safety, quality of life, and potential clinical use of novel therapies for chronic venous insufficiency. Conclusion: Innovative drugs and minimally invasive procedures offer new alternatives for CVI, improving venous function and symptom relief. However, more high-quality clinical research is needed to confirm long-term safety, efficacy, and define optimal treatment protocols, enhancing care standards for venous disorders.